tcf7l1a Antibody

What is TCF7L1/tcf7l1a and what is its function?

TCF7L1 (also known as TCF3) is a 63 kDa member of the TCF/LEF family of proteins that contains one HMG box DNA-binding domain (approximately amino acids 346-414 in humans). It functions as a transcription factor that participates in the Wnt signaling pathway, binding to DNA and acting as a repressor in the absence of CTNNB1 and as an activator in its presence . In zebrafish, tcf7l1a specifically acts cell-autonomously to specify the eye field during embryonic development . The protein is expressed in hair follicles, skin keratinocytes, and at lower levels in stomach epithelium in humans . Functionally, TCF7L1 is necessary for terminal differentiation of epidermal cells, formation of keratohyalin granules, and development of the barrier function of the epidermis .

What are the optimal storage conditions for TCF7L1/tcf7l1a antibodies?

For long-term storage stability, TCF7L1/tcf7l1a antibodies should be stored at -20°C to -80°C, depending on the specific formulation . After reconstitution, most antibodies can be stored at 2-8°C under sterile conditions for approximately 1 month, while longer-term storage (up to 6 months) requires -20°C to -70°C temperatures under sterile conditions . It is critical to avoid repeated freeze-thaw cycles, which can degrade antibody quality and reduce binding efficiency . For recombinant antibodies in PBS-only formulations (without BSA or azide), storage at -80°C is recommended to maintain activity . Always refer to the specific manufacturer's guidelines, as storage conditions may vary slightly between different antibody preparations.

What are the common applications for TCF7L1/tcf7l1a antibodies?

TCF7L1/tcf7l1a antibodies are utilized in several research applications:

• Western Blot: Used to detect TCF7L1 in human tissues including lung, pancreas, and spleen, typically showing bands at approximately 70-75 kDa under reducing conditions .

• Immunocytochemistry/Immunofluorescence: Effective for detecting TCF7L1 in fixed cells, particularly in the nuclei of human embryonic stem cells .

• Cytometric Bead Array: Recombinant antibodies are available as matched pairs for this application .

• ELISAs and Multiplex Assays: Conjugation-ready formats make these antibodies suitable for developing enzyme-linked immunosorbent assays and other multiplex detection methods .

• Mass Cytometry and Multiplex Imaging: Specialized formats are available for these advanced applications .

How should I determine the optimal antibody dilution for my experiment?

Optimal antibody dilutions should be determined empirically for each application and experimental system. For Western blot detection of TCF7L1, starting concentrations of 0.2-1 μg/mL have been reported to be effective . For immunocytochemistry, concentrations around 10 μg/mL have been used successfully for detecting nuclear localization in stem cells .

A systematic dilution series should be performed for your specific application, starting with the manufacturer's recommended concentration. Prepare a series of 2-fold or 5-fold dilutions of the antibody and test each in parallel under identical experimental conditions. Evaluate signal-to-noise ratio and specific band detection (for Western blots) or specific staining pattern (for immunocytochemistry) to determine the optimal concentration that provides maximum specific signal with minimal background .

How can I validate the specificity of TCF7L1/tcf7l1a antibodies in zebrafish models?

Validating antibody specificity in zebrafish models requires multiple complementary approaches:

• Genetic Controls: Utilize tcf7l1a mutant lines as negative controls. Despite the compensatory growth that allows tcf7l1a mutants to develop normal eyes, the absence of the protein provides an excellent control for antibody specificity . Compare antibody staining patterns between wild-type and mutant tissues.

• Western Blot Analysis: Perform Western blots on protein extracts from wild-type and tcf7l1a mutant zebrafish tissues. A specific antibody should detect a band at the predicted molecular weight (~63 kDa) in wild-type but show reduced or absent signal in mutant samples .

• Cross-reactivity Assessment: Test for potential cross-reactivity with tcf7l1b (the paralog resulting from gene duplication in zebrafish) by expressing recombinant proteins and performing immunoprecipitation or Western blot analyses .

• Immunohistochemistry with Morpholino Controls: Perform parallel immunostaining on samples from morpholino-treated embryos (targeting tcf7l1a) and compare with mutant and wild-type samples to confirm staining patterns correlate with known expression domains .

• mRNA Co-localization: Perform in situ hybridization for tcf7l1a mRNA in parallel with antibody staining to confirm that protein detection correlates with mRNA expression domains.

How do TCF7L1/tcf7l1a antibodies perform in tracking compensatory growth mechanisms in eye development?

TCF7L1/tcf7l1a antibodies can be valuable tools for investigating the compensatory growth mechanisms observed in tcf7l1a mutant zebrafish. Despite having an eye field approximately 50% smaller than wild-type embryos, tcf7l1a mutants ultimately develop normal-sized eyes through delayed neurogenesis and prolonged growth .

To effectively track this compensatory process:

• Time-course Immunostaining: Perform immunohistochemistry with TCF7L1 antibodies at multiple developmental stages (eye field specification, optic vesicle formation, and later growth phases) to visualize the temporal dynamics of protein expression relative to other eye development markers.

• Co-immunostaining Approaches: Combine TCF7L1 antibody staining with markers of cell proliferation (phospho-histone H3 or BrdU incorporation) and differentiation (early neuronal markers) to quantify the delay in neurogenesis and extended proliferative period in mutants .

• Quantitative Analysis: Use confocal microscopy and 3D reconstruction to measure cell numbers, tissue volumes, and protein expression levels across developmental stages in wild-type versus mutant embryos.

• Clonal Analysis: Combine sparse genetic labeling techniques with TCF7L1 immunostaining to track the behavior and contribution of individual progenitor cells during the compensatory growth phase.

The research has shown that this compensatory ability is not unique to tcf7l1a mutants but represents a general property of developing optic vesicles, as similar recovery was observed when cells were physically removed from wild-type optic vesicles .

What are the technical considerations for using TCF7L1/tcf7l1a antibodies in multiplex imaging applications?

When implementing TCF7L1/tcf7l1a antibodies in multiplex imaging applications, several technical factors must be considered:

• Antibody Format Selection: Use unconjugated, recombinant monoclonal antibodies in PBS-only buffer (without BSA or azide) when custom conjugation is required for multiplex applications . These preparations allow for specific labeling with fluorophores or other detection molecules.

• Epitope Accessibility: TCF7L1 is predominantly localized to the nucleus, requiring appropriate sample preparation to ensure nuclear permeabilization without destroying epitope recognition sites.

• Species Cross-Reactivity: Carefully select antibody clones based on their documented reactivity. For example, some anti-human TCF7L1 antibodies may not cross-react with zebrafish tcf7l1a or may show differential affinity .

• Antibody Panel Design:

  • Consider spectral overlap when selecting fluorophore conjugates

  • Validate each antibody individually before combining in multiplex panels

  • Include appropriate controls for autofluorescence and non-specific binding

• Signal Amplification Options: For low-abundance targets, consider using secondary amplification methods such as tyramide signal amplification or proximity ligation assays to enhance detection sensitivity.

• Image Acquisition Parameters: Optimize exposure times, detector gain, and other microscopy settings for each channel independently before performing multiplex experiments to prevent signal bleed-through between channels.

What is the relationship between maternal and zygotic expression of tcf7l1a, and how does this impact antibody detection strategies?

The distinction between maternal and zygotic expression of tcf7l1a has significant implications for experimental design and antibody detection strategies:

• Differential Phenotypes: While maternal-zygotic tcf7l1a mutants were initially described as lacking eyes, it has been shown that this phenotype is dependent on genetic background . Zygotic tcf7l1a mutants can develop functional eyes despite having a significantly reduced eye field at early stages .

• Temporal Detection Windows:

  • Maternal protein detection: Requires sampling before the mid-blastula transition (~3-4 hours post-fertilization in zebrafish)

  • Zygotic protein detection: Becomes prominent after the onset of zygotic transcription

• Quantitative Considerations: Antibody-based quantification methods must account for the potential presence of both maternal and zygotic proteins in early embryos. Western blot or immunofluorescence quantification should be interpreted with this dual source in mind.

• Experimental Controls:

  • Use maternal-zygotic mutants (MZ tcf7l1a) as complete negative controls

  • Compare with zygotic mutants (Z tcf7l1a) to distinguish maternal contribution

  • Include wild-type controls for total protein levels

• Detection Sensitivity Requirements: The maternal contribution may be diluted through cell divisions, requiring highly sensitive detection methods for accurate visualization in later developmental stages.

• Alternative Approaches: In cases where antibody detection is challenging, complement with RNA detection methods like in situ hybridization to distinguish between maternal transcripts (present before zygotic genome activation) and zygotic transcription.

How can TCF7L1/tcf7l1a antibodies be used to investigate genetic compensation and redundancy mechanisms?

TCF7L1/tcf7l1a antibodies can be powerful tools for investigating genetic compensation and redundancy mechanisms, particularly in zebrafish models where gene duplication has led to functional redundancy between tcf7l1a and tcf7l1b :

• Paralog-Specific Detection: Use highly specific antibodies that can distinguish between tcf7l1a and tcf7l1b proteins to assess potential compensatory upregulation at the protein level. This requires validation of antibody specificity against recombinant proteins of both paralogs.

• Protein Expression Analysis in Mutant Backgrounds:

  • Quantify tcf7l1b protein levels in tcf7l1a mutants compared to wild-type

  • Assess expression patterns in single versus double mutants

  • Monitor temporal changes in expression throughout development

• Co-immunoprecipitation Studies: Use TCF7L1 antibodies to identify protein interaction partners that may be altered in compensation scenarios, potentially revealing alternative pathways activated in the absence of tcf7l1a.

• Chromatin Immunoprecipitation (ChIP) Applications: Compare genomic binding profiles of tcf7l1a and tcf7l1b in wild-type versus mutant backgrounds to identify shared and unique target genes that may explain functional redundancy or compensation.

• Quantitative Proteomic Approaches: Combine TCF7L1 antibodies with mass spectrometry-based proteomics to assess global protein changes in response to tcf7l1a mutation, potentially identifying additional compensatory mechanisms beyond paralog upregulation.

The research indicates that despite the presence of both tcf7l1a and tcf7l1b genes in zebrafish, there is no evidence for transcriptional upregulation of other tcf genes as a compensatory mechanism in tcf7l1a mutants, suggesting that robustness in eye development is achieved through other mechanisms .

What protocol modifications are recommended for detecting TCF7L1/tcf7l1a in different tissue types?

Detecting TCF7L1/tcf7l1a across different tissue types requires specific protocol adjustments:

For all tissue types:

• Include appropriate negative controls (secondary antibody only, isotype controls, and when possible, tissue from knockout/mutant models)

• Optimize blocking solutions to minimize non-specific binding (typically 3-5% serum from the same species as the secondary antibody)

• For tissues with high autofluorescence (like pancreas), consider adding a quenching step (0.1% sodium borohydride or Sudan Black B treatment)

• Adjust incubation times based on tissue thickness and antibody penetration requirements

How can I troubleshoot non-specific binding issues with TCF7L1/tcf7l1a antibodies?

Non-specific binding is a common challenge when working with transcription factor antibodies like TCF7L1/tcf7l1a. Here's a methodological approach to troubleshooting:

• Validate Antibody Specificity:

  • Perform Western blots on positive control samples (human lung, pancreas, or spleen tissue for TCF7L1; zebrafish embryo lysates for tcf7l1a)

  • Confirm the detection of a single band at the expected molecular weight (~63-75 kDa)

  • Test on knockout/mutant samples as negative controls when available

• Optimize Blocking Conditions:

  • Test different blocking agents (BSA, normal serum, commercial blockers)

  • Increase blocking time (from 1 hour to overnight at 4°C)

  • Include 0.1-0.3% Triton X-100 or 0.05% Tween-20 in blocking solutions to reduce hydrophobic interactions

• Antibody Dilution and Incubation:

  • Perform a titration series to determine optimal antibody concentration

  • Extend primary antibody incubation time while reducing concentration

  • Switch from room temperature to 4°C overnight incubation

• Washing Optimization:

  • Increase number and duration of wash steps

  • Add detergent (0.1% Triton X-100) to wash buffers

  • Consider using high-salt wash buffers (up to 500 mM NaCl) to disrupt low-affinity non-specific interactions

• Pre-absorption Controls:

  • Incubate antibody with recombinant TCF7L1 protein prior to use

  • Compare staining patterns between pre-absorbed and non-absorbed antibody

• Secondary Antibody Considerations:

  • Use highly cross-adsorbed secondary antibodies to minimize species cross-reactivity

  • Test alternative secondary antibody formats or sources

• Tissue-Specific Treatments:

  • For tissues with high endogenous biotin, include an avidin/biotin blocking step

  • For tissues with high endogenous peroxidase activity, include a peroxidase quenching step

What are the recommended protocols for using TCF7L1/tcf7l1a antibodies in Western blot applications?

Based on the search results, here is a detailed protocol for Western blot detection of TCF7L1/tcf7l1a:

Sample Preparation:

• Extract proteins from tissues of interest (human lung, pancreas, spleen, or zebrafish embryos) using a standard lysis buffer containing protease inhibitors

• Quantify protein concentration using Bradford or BCA assay

• Prepare samples (20-50 μg total protein) in reducing SDS-PAGE loading buffer

• Heat samples at 95°C for 5 minutes

Gel Electrophoresis and Transfer:

• Separate proteins on 8-10% SDS-PAGE gels (optimal for the 63-75 kDa TCF7L1 protein)

• Transfer to PVDF membrane at 100V for 60-90 minutes in standard transfer buffer

Blocking and Antibody Incubation:

• Block membrane in 5% non-fat dry milk or 5% BSA in TBST for 1 hour at room temperature

• Incubate with primary antibody:

  • For monoclonal anti-human TCF7L1/TCF3: Use at 1 μg/mL in blocking buffer

  • For polyclonal anti-human TCF7L1: Use at 0.2 μg/mL in blocking buffer

  • For recombinant antibodies: Optimize starting at 0.5-1 μg/mL

• Incubate overnight at 4°C with gentle rocking

Detection:

• Wash membrane 4-5 times with TBST, 5 minutes each

• Incubate with appropriate HRP-conjugated secondary antibody:

  • Anti-Mouse IgG for monoclonal antibodies (e.g., Catalog # HAF007)

  • Anti-Sheep IgG for polyclonal antibodies (e.g., Catalog # HAF016)

• Dilute secondary antibody 1:2000-1:5000 in blocking buffer and incubate for 1 hour at room temperature

• Wash membrane 4-5 times with TBST, 5 minutes each

• Develop using enhanced chemiluminescence (ECL) substrate

• Expect to observe a specific band at approximately 70-75 kDa for TCF7L1

Recommended Controls:

• Positive control: Include human lung, pancreas, or spleen tissue lysates

• Negative control: Include lysate from tissue known not to express TCF7L1

• Loading control: Probe for housekeeping protein such as β-actin or GAPDH

Special Considerations:

• Use Immunoblot Buffer Group 1 for optimal results as specified in the technical information

• Perform all experiments under reducing conditions for consistent results

How can TCF7L1/tcf7l1a antibodies be used to study the Wnt signaling pathway in developmental contexts?

TCF7L1/tcf7l1a antibodies provide valuable tools for investigating Wnt signaling dynamics in developmental contexts:

• Co-immunoprecipitation for Protein Interaction Studies:

  • Use TCF7L1 antibodies to pull down the protein and its binding partners

  • Analyze CTNNB1 (β-catenin) interaction under different Wnt signaling conditions

  • Compare wild-type versus mutant forms to assess functional interactions

• ChIP-seq for Genomic Binding Site Identification:

  • Use TCF7L1 antibodies for chromatin immunoprecipitation followed by sequencing

  • Map binding sites genome-wide in different developmental contexts

  • Compare TCF7L1 binding profiles in the presence or absence of Wnt pathway activation

  • Correlate binding patterns with gene expression changes

• Spatial and Temporal Expression Analysis:

  • Track TCF7L1 protein expression and subcellular localization throughout development

  • In zebrafish, monitor dynamic expression changes during eye field specification and subsequent eye development

  • Correlate with expression of other Wnt pathway components

• Functional Studies in Zebrafish:

  • Use antibodies to validate tcf7l1a knockout or knockdown efficiency

  • Investigate compensatory mechanisms involving tcf7l1b or other TCF family members

  • Monitor protein expression changes in response to Wnt pathway modulators

• Transcriptional Activity Assessment:

  • Combine TCF7L1 antibody staining with reporters of Wnt target gene activation

  • Correlate TCF7L1 nuclear localization with transcriptional repression (in absence of CTNNB1) or activation (in presence of CTNNB1)

It is important to note that TCF7L1 functions as a repressor in the absence of CTNNB1 (β-catenin) and as an activator in its presence, making it a crucial regulator of Wnt-dependent gene expression during development .

What are the implications of studying TCF7L1/tcf7l1a in different genetic backgrounds?

The study of TCF7L1/tcf7l1a across different genetic backgrounds reveals important insights about genetic modifiers and context-dependent function:

• Phenotypic Variability:

  • The tcf7l1a mutation's phenotypic expression is highly dependent on genetic background, with maternal-zygotic mutants originally described as eyeless in some backgrounds but developing functional eyes in others

  • This variability highlights the importance of standardizing genetic backgrounds in experimental designs

• Modifier Gene Identification:

  • Forward genetic screens have identified mutations in genes like hesx1, cct5, and gdf6a that produce synthetic phenotypes when combined with tcf7l1a mutations

  • These genetic interactions reveal functional relationships that may not be apparent in single-gene studies

• Experimental Design Considerations:

  • When using TCF7L1/tcf7l1a antibodies across different genetic backgrounds:

    • Include appropriate wild-type controls from each genetic background

    • Quantify protein expression levels to detect subtle differences

    • Consider potential epitope variations that might affect antibody binding

• Translational Implications:

  • Human genetic variation in TCF7L1 may similarly result in context-dependent phenotypes

  • Understanding background effects in model organisms can inform human genetic studies of TCF7L1-related conditions

• Experimental Approach:

  • Perform parallel antibody validation in each genetic background

  • Establish baseline expression patterns and levels specific to each background

  • Consider epitope sequencing to identify potential variations that might affect antibody binding

• Data Interpretation Guidelines:

  • Account for background-specific differences when comparing experimental results

  • Report genetic background details in publications to ensure reproducibility

  • Consider using congenic lines to isolate modifier effects

The zebrafish research demonstrates that genetic background can significantly modify the tcf7l1a mutant phenotype, emphasizing the importance of controlling for genetic background effects in experimental design and interpretation .

How can TCF7L1/tcf7l1a antibodies contribute to understanding tissue regeneration mechanisms?

TCF7L1/tcf7l1a antibodies can provide valuable insights into tissue regeneration mechanisms, particularly in understanding compensatory growth and regenerative capacity:

• Monitoring Compensatory Growth Mechanisms:

  • The zebrafish tcf7l1a mutant model reveals remarkable compensatory growth capability, where a severely reduced eye field can still develop into functional eyes through delayed neurogenesis and prolonged growth

  • TCF7L1 antibodies can track protein expression during this compensatory process, revealing temporal dynamics of growth regulation

• Stem Cell Regulation Studies:

  • TCF7L1 expression in human embryonic stem cells suggests a role in maintaining pluripotency or directing differentiation

  • Antibodies can be used to monitor TCF7L1 levels during stem cell differentiation toward specific lineages

• Wnt Pathway Dynamics During Regeneration:

  • As a key transcription factor in the Wnt pathway, TCF7L1 likely plays important roles in tissue regeneration contexts

  • Antibodies can map spatial and temporal changes in TCF7L1 expression and subcellular localization during regenerative processes

• Tissue-Specific Regenerative Responses:

  • Compare TCF7L1 expression and activity across tissues with different regenerative capacities

  • Investigate whether variations in TCF7L1 expression correlate with regenerative potential

• Experimental Approaches for Regeneration Studies:

  • In vivo injury models: Use TCF7L1 antibodies to track protein expression changes following tissue damage

  • Cell ablation experiments: Monitor TCF7L1 expression during compensatory growth after targeted cell removal

  • Lineage tracing: Combine TCF7L1 immunostaining with genetic lineage markers to identify cells contributing to regeneration

  • Functional manipulation: Compare regenerative outcomes when TCF7L1 is inhibited or activated during the regenerative process

The zebrafish study demonstrates that developing optic vesicles have a remarkable ability to compensate for early cell loss, whether through genetic means (tcf7l1a mutation) or physical removal of cells . This compensatory growth represents a fundamental property of developing tissues that may inform regenerative medicine approaches.

What are the critical controls needed when using TCF7L1/tcf7l1a antibodies in zebrafish research?

When using TCF7L1/tcf7l1a antibodies in zebrafish research, incorporating appropriate controls is essential for reliable interpretation:

• Genetic Controls:

  • Negative control: tcf7l1a mutant zebrafish tissue - should show reduced or absent staining

  • Dosage control: Heterozygous tcf7l1a+/- samples to assess intermediate expression levels

  • Redundancy control: tcf7l1b mutant and tcf7l1a/tcf7l1b double mutant tissues to assess paralog-specific staining

• Technical Controls:

  • Antibody specificity control: Pre-absorption with recombinant tcf7l1a protein

  • Secondary antibody control: Omit primary antibody to assess non-specific secondary binding

  • Isotype control: Use non-specific antibody of same isotype and concentration

• Developmental Stage Controls:

  • Temporal expression controls: Sample tissues at multiple developmental timepoints

  • Maternal contribution control: Compare pre-zygotic genome activation versus post-activation stages

  • Tissue-specific controls: Include tissues known to be positive or negative for tcf7l1a expression

• Experimental Manipulation Controls:

  • Morpholino validation: Compare antibody staining in morpholino-injected versus mutant embryos

  • mRNA rescue experiments: Assess restoration of protein expression following mRNA injection

  • Drug treatment controls: Include appropriate vehicle controls when using Wnt pathway modulators

• Cross-species Controls:

  • If using antibodies raised against human TCF7L1, validate cross-reactivity with zebrafish tcf7l1a

  • Include control experiments with human cell lines/tissues when available

  • Consider epitope sequence conservation when interpreting results

These comprehensive controls ensure accurate interpretation of antibody staining patterns in zebrafish models and help distinguish between specific signal and background or non-specific staining.

How can TCF7L1/tcf7l1a antibodies be utilized in single-cell analysis techniques?

TCF7L1/tcf7l1a antibodies can be effectively incorporated into various single-cell analysis techniques, providing insights into cellular heterogeneity and protein expression at individual cell resolution:

• Flow Cytometry and Cell Sorting:

  • Use fluorophore-conjugated TCF7L1 antibodies for intracellular staining

  • Optimize fixation and permeabilization protocols for nuclear transcription factor detection

  • Combine with surface markers to identify specific cell populations expressing TCF7L1

  • Sort TCF7L1-positive cells for downstream molecular analysis

• Mass Cytometry (CyTOF):

  • Conjugate TCF7L1 antibodies with rare earth metals for mass cytometry

  • Use in conjunction with other transcription factor and signaling pathway markers

  • Develop optimized staining protocols for metal-conjugated nuclear antibodies

  • The conjugation-ready format of some TCF7L1 antibodies makes them ideal for this application

• Single-Cell Immunofluorescence:

  • Perform quantitative immunofluorescence on dissociated cells

  • Measure nuclear TCF7L1 intensity at the single-cell level

  • Correlate with other markers using multiparameter imaging

  • Implement automated image analysis for high-throughput quantification

• In Situ Techniques:

  • Proximity Ligation Assay (PLA): Detect TCF7L1 interactions with binding partners in situ

  • Imaging Mass Cytometry: Analyze tissue sections with metal-labeled antibodies

  • Multiplexed Immunofluorescence: Combine TCF7L1 with other markers using cyclic immunofluorescence or spectral unmixing

• Integration with Single-Cell Genomics:

  • CITE-seq approach: Combine protein detection (including TCF7L1) with single-cell RNA sequencing

  • Single-cell Western blot: Validate antibody specificity at single-cell resolution

  • Spatial transcriptomics integration: Correlate TCF7L1 protein localization with gene expression patterns

For optimal results in single-cell applications, use highly specific monoclonal or recombinant antibodies with validated single-cell protocols. The unconjugated recombinant monoclonal antibodies available in PBS-only formulations are particularly well-suited for custom conjugation needed in many single-cell techniques .